Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Current Assets (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Current Assets data on record, last reported at $96.3 million in Q4 2025.

  • For Q4 2025, Current Assets fell 23.53% year-over-year to $96.3 million; the TTM value through Dec 2025 reached $96.3 million, down 23.53%, while the annual FY2025 figure was $96.3 million, 23.53% down from the prior year.
  • Current Assets reached $96.3 million in Q4 2025 per ACRS's latest filing, down from $100.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $259.4 million in Q2 2022 and bottomed at $96.3 million in Q4 2025.
  • Average Current Assets over 5 years is $160.8 million, with a median of $133.7 million recorded in 2021.
  • Peak YoY movement for Current Assets: soared 256.62% in 2021, then tumbled 52.03% in 2023.
  • A 5-year view of Current Assets shows it stood at $205.0 million in 2021, then increased by 12.93% to $231.6 million in 2022, then plummeted by 44.35% to $128.9 million in 2023, then fell by 2.25% to $126.0 million in 2024, then decreased by 23.53% to $96.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $96.3 million in Q4 2025, $100.6 million in Q3 2025, and $104.2 million in Q2 2025.